American Cancer Society. Cancer Facts and Figures 2018. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed March 1, 2018.
Biswas T, Sharma N, Machtay M. Controversies in the management of stage III non-small-cell lung cancer. Expert Rev Anticancer Ther 2014;14:333–347.
Patel AP, Crabtree TD, Bell JM, . National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer. J Thorac Oncol 2014;9:612–621.
Berry MF, Worni M, Pietrobon R, . Variability in the treatment of elderly patients with stage IIIA (N2) non-small cell lung cancer. J Thorac Oncol 2013;8:744–752.
Albain KS, Swann RS, Rusch VW, . Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379–386.
Kumar SS, Higgins KA, McGarry RC. Emerging therapies for stage III non-small cell lung cancer: stereotactic body radiation therapy and immunotherapy. Front Oncol 2017;7:197.
Birkmeyer JD, Siewers AE, Finlayson EV, . Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128–1137.
Santana-Davila R, Martins R. Treatment of stage IIIA non-small-cell lung cancer: a concise review for the practicing oncologist. J Oncol Pract 2016;12:601–606.
Bach PB, Cramer LD, Schrag D, . The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181–188.
Farjah F, Flum DR, Varghese TK Jr, . Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 2009;87:995–1004, discussion 1005–1006.
Van Schil PE. Stage IIIA-N2 non-small-cell lung cancer: from ‘surprise’ involvement to surgical nightmare. Eur J Cardiothorac Surg 2016;49:1613–1614.
Eaton BR, Pugh SL, Bradley JD, . Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst 2016;108:djw034.
Myrdal G, Gustafsson G, Lambe M, . Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg 2001;20:694–699.
Shi W, Zhang W, Sun H, . Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2012;10:265.
Lee ES, Park SI, Kim YH, . Comparison of operative mortality and complications between bronchoplastic lobectomy and pneumonectomy in lung cancer patients. J Korean Med Sci 2007;22:43–47.
Camposilvan I, Akhtar-Danesh N, Schneider L, . The effect of surgeon volume on procedure selection in non–small cell lung cancer surgeries. J Thorac Cardiovasc Surg 2015;150:507–513.
Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 2011;364:2128–2137.
Wang EH, Rutter CE, Corso CD, . Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small-cell lung cancer. J Thorac Oncol 2015;10:937–943.